STOCK TITAN
  1. Home
  2. News
  3. BRTX

Biorestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.

BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.

Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.

Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.

Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.

News

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Rhea-AI Summary
BioRestorative Therapies, Inc. (BRTX) has been granted a notice of allowance for a U.S. patent related to the Company’s metabolic ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes. This will be the fourth U.S. patent granted under this particular patent family, covering methods of using differentiated human brown fat adipocytes to screen and identify compounds that can activate and regulate metabolic activity. The Company sees this as an important milestone, providing them with tools to screen large libraries of compounds targeting metabolic disorders such as obesity, potentially leading to the development of drugs targeting weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
-
News

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Rhea-AI Summary
BioRestorative Therapies CEO to present at ROTH MKM Healthcare Opportunities Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
News

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Rhea-AI Summary
BioRestorative Therapies strategically positions itself for future growth with expanding manufacturing capacity, increased demand for BRTX-100, and advancements in intellectual property. Roth MKM projects a stock price target of $15 over the next 12 months, compared to the current $2.59. The company had pro forma cash of $13.4 million and $3.3 million remaining in its at-the-market facility. BioRestorative received a unanimous recommendation to continue its Phase 2 trial for evaluating BRTX-100 in patients with chronic lumbar disc disease. The company has made efforts to ramp up manufacturing and quality control capacity and has obtained a license to serve as a tissue bank for processing mesenchymal stem cells. The global mesenchymal stem cell market is expected to grow at a CAGR of 12.8% from 2023 to 2030. BioRestorative can expand its clinical operations and has collaborated with Northwell Health for trial sites. Other companies in the space include Mesoblast, Brainstorm Cell Therapeutic, and Longeveron.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
News

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Rhea-AI Summary
BioRestorative enters supply agreement with Evolutionary Biologics for cosmetic applications, representing initial venture into $62.8B global aesthetics market. Initial order of 5,000 vials will have positive financial impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.37%
Tags
none
-
News

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Rhea-AI Summary
BioRestorative announces site activation for BRTX-100 trial in New York, allowing patient recruitment and enrollment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
clinical trial
-
News

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Rhea-AI Summary
BioRestorative Therapies aims to provide better treatment options for chronic pain without the need for opioids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
none
News

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) insiders, including Dale Broadrick and CEO Lance Alstodt, demonstrate confidence in the company's future by acquiring shares. Insider buying signals positive outlook and sentiment, providing valuable insights for evaluating potential company performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
News

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
News

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) has been granted a license by the New York State Department of Health to operate as a tissue bank, allowing the processing of mesenchymal stem cells for clinical use. This makes BioRestorative the first facility in New York State licensed to do so, setting it apart from competitors. Mesenchymal Stem Cells have the potential to be used in the development of treatments for various diseases, and BioRestorative is excited about the possibilities this presents for their business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
none
News

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

Rhea-AI Summary
BioRestorative Therapies, Inc. has entered into a definitive agreement for the sale of 685,033 shares of common stock at an offering price of $3.03 per share, resulting in gross proceeds of approximately $2.1 million. The proceeds will be used for clinical trials, pre-clinical research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
offering
Stock BRTX logo
Biorestorative Therapies Inc

Nasdaq:BRTX

BRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

BRTX Stock Data

12.11M
5.59M
27.7%
13.91%
10.35%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States
MELVILLE